Pharmacological Treatments for Autism Spectrum Disorder: Will Emerging Approaches Yield New Treatments?

被引:0
作者
Rocco G Gogliotti
P Jeffrey Conn
机构
[1] Vanderbilt University Medical Center,Department of Pharmacology
[2] Nashville,undefined
[3] TN,undefined
[4] USA,undefined
[5] Vanderbilt Center for Neuroscience Drug Discovery,undefined
[6] Vanderbilt University Medical Center,undefined
来源
Neuropsychopharmacology | 2016年 / 41卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:376 / 377
页数:1
相关论文
共 42 条
[1]  
Castro J(2014)Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett Syndrome Proc Natl Acad Sci USA 111 9941-9946
[2]  
Garcia RI(2014)Synaptic, transcriptional and chromatin genes disrupted in autism Nature 515 209-215
[3]  
Kwok S(2015)NNZ-2566, a novel analog of (1-3) IGF-1, as a potential therapeutic agent for fragile X syndrome Neuromolecular Med 17 71-82
[4]  
Banerjee A(2014)The contribution of de novo coding mutations to autism spectrum disorder Nature 515 216-221
[5]  
Petravicz J(2014)The challenges of clinical trials in fragile X syndrome Psychopharmacology 231 1237-1250
[6]  
Woodson J(2014)Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome Proc Natl Acad Sci USA 111 4596-4601
[7]  
De Rubeis S(2014)A BDNF loop-domain mimetic acutely reverses spontaneous apneas and respiratory abnormalities during behavioral arousal in a mouse model of Rett syndrome Dis Model Mech 7 1047-1055
[8]  
He X(undefined)undefined undefined undefined undefined-undefined
[9]  
Goldberg AP(undefined)undefined undefined undefined undefined-undefined
[10]  
Poultney CS(undefined)undefined undefined undefined undefined-undefined